This study aimed to explore the efficacy of lamivudine + zidovudine plus nevirapine and efavirenz in the treatment hf human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS). A total of 100 patients with HIV/AIDS admitted to our hospital from June 2021 to September 2024 were selected and randomly assigned into nevirapine and efavirenz groups (n = 50 per group). The nevirapine group was treated with lamidudine plus zidovudine combined with nevirapine, and the efavirenz group was treated with lamidudine plus zidovudine plus efavirenz. The primary outcomes measured were the changes of lymphocyte count and adverse effects after 3 months of treatment. There was no statistical difference in baseline information between the 2 groups. After treatment, CD3 + and CD4 + levels were higher in the nevirapine group than in the efavirenz group ( P <.05, 95% CI: 45.2–98.7 for CD3 + and 32.8–76.4 for CD4+), and CD8 + levels were lower in the nevirapine group than in the efavirenz group ( P <.05); the overall incidence of adverse effects in the nevavirapine group was significantly lower than that in the efavirenz group ( P <.05). In HIV/AIDS patients, treatment with lamivudine + zidovudine combined with nevirapine resulted in significantly improved CD4 + T cell counts, enhanced immune function, and fewer adverse reactions compared to treatment with lamivudine + zidovudine plus efavirenz, suggesting superior clinical value of the nevirapine-containing regimen.
Zhu et al. (Fri,) studied this question.